Travere Therapeutics, Inc.
TVTX
Classificação em ações
#3574
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Preço da ação
$51.05
Valor de mercado
$4.81B
Variação (1 dia)
1.11%
Variação (1 ano)
83.05%
País
US
Negociar Travere Therapeutics, Inc. (TVTX)
Categoria
Healthcare
Rácio P/S de Travere Therapeutics, Inc. (TVTX)
Rácio P/S em October 2026 TTM: 8.38
De acordo com os relatórios financeiros mais recentes e o preço das ações da Travere Therapeutics, Inc., o rácio P/S atual (TTM) é 8.38. No final de 2023, o rácio P/S era 4.60.
Histórico do rácio P/S da Travere Therapeutics, Inc. de 2009 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 8.38 | 42.23% |
| 2024 | 5.89 | 28.21% |
| 2023 | 4.60 | -27.31% |
| 2022 | 6.32 | -22.53% |
| 2021 | 8.16 | 24.96% |
| 2020 | 6.53 | 90.53% |
| 2019 | 3.43 | -38.43% |
| 2018 | 5.57 | 5.64% |
| 2017 | 5.27 | 0.57% |
| 2016 | 5.24 | -19.11% |
| 2015 | 6.48 | -40.37% |
| 2014 | 10.87 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | 19.63% |
US
|
|
| 40.55 | 384.06% |
US
|
|
| 3.96 | -52.72% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 21.12% |
NL
|
